SMILES
stringlengths 2
1.49k
| Question
stringlengths 40
251
| Answer
stringlengths 1
191
|
|---|---|---|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the definition of this compound's USAN stem?
|
allosteric cardiac myosin modulators
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Does this compound satisfy the rule-of-three criteria?
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many hydrogen bond acceptors does this compound have?
|
4
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts?
|
0
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is it known whether this drug is administered parenterally?
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is it known whether this drug is applied topically?
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is this compound a small molecule polymer, such as polystyrene sulfonate?
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the molecular formula of this compound, including any salt that it may have?
|
C15H19N3O2
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is this molecule characterized by a small molecular structure or a protein sequence?
|
It has a small molecule structure.
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms.
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
|
Approved
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the polar surface area (PSA) value of this compound?
|
66.89
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many aromatic rings does this compound have?
|
2
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target?
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
|
5
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is there a black box warning associated with this drug?
|
Yes
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications?
|
Yes
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)?
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many hydrogen bond donors does this compound have?
|
2
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the first recorded year of approval for this drug?
|
2022
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound?
|
0
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the calculated ALogP value for this compound?
|
2.29
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many heavy (non-hydrogen) atoms does this compound have?
|
20
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is this compound an acid, a base, or neutral?
|
NEUTRAL
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Determine the type of availability for this drug.
|
prescription only
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is it known whether this drug is taken orally?
|
Yes
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Is the drug administered in this specific form, such as a particular salt?
|
Yes
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Determine if this compound is a prodrug.
|
No
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Which USAN substem can this drug or clinical candidate name be matched with?
|
-camten
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the molecular weight of this compound's parent molecule?
|
273.34
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)?
|
2
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown.
|
Small molecule
|
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
|
Please provide a description of this drug's mechanism of action.
|
Cardiac myosin inhibitor
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many aromatic rings does this compound have?
|
0
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many rotatable bonds does this compound have?
|
7
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Does this compound satisfy the rule-of-three criteria?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many hydrogen bond acceptors does this compound have?
|
4
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is it known whether this drug is administered parenterally?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is it known whether this drug is applied topically?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown.
|
Unknown
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is this compound a small molecule polymer, such as polystyrene sulfonate?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the molecular weight of this compound's parent molecule?
|
146.24
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the calculated ALogP value for this compound?
|
-1.92
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is this molecule characterized by a small molecular structure or a protein sequence?
|
It has a small molecule structure.
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
|
Approved
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality.
|
Unknown chirality
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is there a black box warning associated with this drug?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Determine the type of availability for this drug.
|
unknown
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Determine if this compound is a prodrug.
|
It is not a drug
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the molecular formula of this compound, including any salt that it may have?
|
C6H22Cl4N4
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)?
|
6
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the polar surface area (PSA) value of this compound?
|
76.1
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
What is the first recorded year of approval for this drug?
|
2022
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound?
|
0
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is it known whether this drug is taken orally?
|
No
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is this compound an acid, a base, or neutral?
|
BASE
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
|
4
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is the drug administered in this specific form, such as a particular salt?
|
Yes
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts?
|
1
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Please provide a description of this drug's mechanism of action.
|
Copper chelating agent
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms.
|
It is not a drug
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many hydrogen bond donors does this compound have?
|
4
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target?
|
It is not a drug
|
Cl.Cl.Cl.Cl.NCCNCCNCCN
|
How many heavy (non-hydrogen) atoms does this compound have?
|
10
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many rotatable bonds does this compound have?
|
4
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality.
|
Single stereoisomer
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Does this compound satisfy the rule-of-three criteria?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts?
|
0
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is it known whether this drug is administered parenterally?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is it known whether this drug is applied topically?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)?
|
1
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Please provide a description of this drug's mechanism of action.
|
Orexin receptor 1 antagonist
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is this compound a small molecule polymer, such as polystyrene sulfonate?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is this molecule characterized by a small molecular structure or a protein sequence?
|
It has a small molecule structure.
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms.
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
|
Approved
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is there a black box warning associated with this drug?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the molecular weight of this compound's parent molecule?
|
450.93
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many hydrogen bond acceptors does this compound have?
|
6
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications?
|
Yes
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)?
|
8
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)?
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the first recorded year of approval for this drug?
|
2022
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound?
|
0
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Please provide a description of this drug's mechanism of action.
|
Orexin receptor 2 antagonist
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is this compound an acid, a base, or neutral?
|
NEUTRAL
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Determine the type of availability for this drug.
|
prescription only
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the polar surface area (PSA) value of this compound?
|
88.93
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many aromatic rings does this compound have?
|
4
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many heavy (non-hydrogen) atoms does this compound have?
|
32
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is it known whether this drug is taken orally?
|
Yes
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Is the drug administered in this specific form, such as a particular salt?
|
Yes
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
Determine if this compound is a prodrug.
|
No
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the molecular formula of this compound, including any salt that it may have?
|
C23H24Cl2N6O2
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the calculated ALogP value for this compound?
|
4.27
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
How many hydrogen bond donors does this compound have?
|
1
|
COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl
|
What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown.
|
Small molecule
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.